Needham Reiterates Hold on Amphastar Pharma
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Hold rating on Amphastar Pharma (NASDAQ:AMPH).
May 22, 2024 | 3:53 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Needham analyst Serge Belanger has reiterated a Hold rating on Amphastar Pharma. This suggests that the analyst does not see significant upside or downside potential in the short term.
The Hold rating indicates that the analyst believes the stock is fairly valued at its current price. This typically means that there are no immediate catalysts expected to drive the stock price significantly up or down.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100